אגיספור ג'ל
padagis israel pharmaceuticals ltd, israel - bifonazole - ג'ל - bifonazole 1 %w/w - bifonazole - bifonazole - broad spectrum antimycotic agent.
אגיספור תמיסה
padagis israel pharmaceuticals ltd, israel - bifonazole - תמיסה - bifonazole 1 %w/v / 100 ml - bifonazole - bifonazole - broad spectrum antimycotic agent.
קרטוספור
padagis israel agencies ltd, israel - bifonazole; urea - משחה - urea 40 %; bifonazole 1 % - bifonazole - bifonazole - for nail stripping and antifungal treatment of fungal infections of the finger nails and toe nails.
מנטקס קרם
padagis israel pharmaceuticals ltd, israel - butenafine hydrochloride - קרם - butenafine hydrochloride 1 % - butenafine - butenafine - interdigital tinea pedis, tinea coporis, tinea cruris . (treatment in tinea coporis and tinea cruris is limited to up to 4 weeks).
הידרואגיסטן קרם
padagis israel pharmaceuticals ltd, israel - clotrimazole; hydrocortisone acetate - קרם - clotrimazole 1 %; hydrocortisone acetate 1 % - hydrocortisone - hydrocortisone - skin inflammation involving fungal infection
נרידרם קרם
padagis israel pharmaceuticals ltd, israel - diflucortolone valerate - קרם - diflucortolone valerate 0.1 %w/w / 100 g - diflucortolone - diflucortolone - corticoid responsive dermatoses in the absence of infection
נרידרם משחה
padagis israel pharmaceuticals ltd, israel - diflucortolone valerate - משחה - diflucortolone valerate 0.1 g / 100 g - diflucortolone - diflucortolone - corticoid responsive dermatoses in the absence of infection
הרגיין % 5
padagis israel pharmaceuticals ltd, israel - minoxidil - תמיסה - minoxidil 5 % - minoxidil - minoxidil - hair regrowth treatment for men.
אגיסטן וי % 2 קרם וגינלי
padagis israel pharmaceuticals ltd, israel - clotrimazole - קרם וגינלי - clotrimazole 2 % - clotrimazole - clotrimazole - broad spectrum antimycotic with fungicidal action
סברילן
padagis israel pharmaceuticals ltd, israel - vigabatrin - טבליות מצופות פילם - vigabatrin 500 mg - vigabatrin - vigabatrin - treatment in combination with other anti epileptic drugs for patients with resistant partial epilepsy with or without secondary generalisation, that is where all other appropriate drug combinations have proven inadeqate or have not been tolerated.